LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lineage Cell Therapeutics Inc (LCTX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown positive revenue growth and extended its cash runway, its financial performance is still challenged by significant net losses and declining EPS. Additionally, technical indicators and trading sentiment do not provide a compelling entry point. Therefore, it is recommended to hold off on buying until more favorable signals emerge.
The MACD is positive but contracting, indicating a weakening bullish trend. RSI is neutral at 46.089, suggesting no clear momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level of 1.862, with resistance at 1.963 and support at 1.761. Overall, the technical indicators do not strongly favor a buy at this time.
Revenue increased significantly by 130.40% YoY in Q4 2025, driven by collaboration revenue from Roche.
The GAlette study has expanded to 10 clinical sites, indicating progress in clinical trials.
The company extended its cash runway to Q2 2028, ensuring operational stability.
Net income dropped significantly by -126.00% YoY, and EPS fell to 0, reflecting profitability challenges.
R&D expenses increased substantially, contributing to a net loss of $63.5 million.
The consensus EPS estimate for Q4 was -$0.04, highlighting ongoing challenges in achieving profitability.
In Q4 2025, revenue increased to $6.6 million, up 130.40% YoY, primarily due to collaboration revenue. However, net income dropped to $851,000, down -126.00% YoY, and EPS fell to 0, down -100.00% YoY. Gross margin improved slightly to 99%, up 4.62% YoY. Overall, while revenue growth is promising, profitability remains a significant concern.
No specific analyst rating or price target changes were provided. However, the company's historical performance indicates it has beaten EPS estimates 75% of the time and revenue estimates 63% of the time over the past two years, suggesting mixed sentiment among analysts.
